The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2020 | Evolving role of HER2 targeted therapies in gastroesophageal cancers

Name: Evolving role of HER2 targeted therapies in gastroesophageal cancers
Uploaded: 2020-05-28T00:00:00Z
Duration: 10 min 8 s
Description: Barbara Burtness, MD, of Yale Cancer Center, New Haven, CT, discusses advancements in targeting HER2 for the treatment of gastroesophageal cancers. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Barbara Burtness • 28 May 2020

ASCO 2020

Gastrointestinal Cancer Trastuzumab

Barbara Burtness, MD, of Yale Cancer Center, New Haven, CT, discusses advancements in targeting HER2 for the treatment of gastroesophageal cancers. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).